Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'Resovist' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Resovist' found in 1 term [] and 5 definitions []
1 - 5 (of 6)     next
Result Pages : [1]  [2]
Searchterm 'Resovist' was also found in the following service: 
spacer
Forum  (2)  
 
Resovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions. In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.
See also Superparamagnetic Iron Oxide.

Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.

Drug Information and Specification
NAME OF COMPOUND Ferrixan [Ferucarbotran], carboxydextran coated iron oxide nanoparticles
DEVELOPER Bayer Schering Pharma AG
CENTRAL MOIETY Fe2+
CONTRAST EFFECT T2/T1, Predominantly negative enhancement
RELAXIVITY r1=25.4, r2=151,
PHARMACOKINETIC RES-directed
OSMOLALITY 333 mosm/kg
CONCENTRATION 0.5 mol Fe/L
DOSAGE Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml
PREPARATION Finished product
INDICATION Liver lesions
DISTRIBUTOR See below
PRESENTATION Pre-filled syringes of 0.9 and 1.4 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Resovist® ? -
Japan Resovist® approved -
EU Resovist® approved -
Australia Resovist® Approved -

spacer
 
• Share the entry 'Resovist®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast Agents
Sunday, 30 November 2003   by rsna2003.rsna.org    
MRI Resources 
NMR - Supplies - Diffusion Weighted Imaging - Used and Refurbished MRI Equipment - Implant and Prosthesis pool - Bioinformatics
 
Cliavist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MRI contrast agent (another trade name for Resovist®). See Resovist®.
spacer

• View the DATABASE results for 'Cliavist™' (2).Open this link in a new window

MRI Resources 
Absorption and Emission - Safety pool - Examinations - Knee MRI - Most Wanted - Education pool
 
FerucarbotranInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: SHU 555 A, generic name: Ferucarbotran
A RES-directed MRI contrast agent (SPIO) made-up of a colloidal sol of iron oxide nanoparticles coated with carboxydextran (Resovist®, Cliavist™).
It is used for the detection and characterization of especially small focal liver lesions and offers the opportunity to make a reliable diagnosis at a very early stage of patients with suspected liver tumors.
Bayer Schering Pharma AG announced that it has received marketing approval for the liver-specific contrast agent Resovist® in Japan. See Contrast Agents and Superparamagnetic Contrast Agents.

spacer

• View the DATABASE results for 'Ferucarbotran' (4).Open this link in a new window

Searchterm 'Resovist' was also found in the following service: 
spacer
Forum  (2)  
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Magnevist® enteral
Magnevist®
Gadovist®
Resovist® -
Primovist™,Eovist®
Vasovist® -
Gadofluorine
Gadophrin
Gadomer 17
Gd-DTPA-Polylysine
Supravist™

Contact Information
MAIL Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE +49-30-46-81-2431
FAX +49-30-46-81-8195
ONLINE www.bayerscheringpharma.de/scripts/pages/en/index.php
spacer

• View the DATABASE results for 'Bayer Schering Pharma AG' (22).Open this link in a new window


• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
MRI Resources 
Functional MRI - MRI Technician and Technologist Jobs - General - DICOM - Crystallography - Mobile MRI
 
SHU 555 CInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: SHU 555 C, preliminary trade name: Supravist™, concentration: 0.5 mol Fe/L
SHU 555 C (Bayer Schering Pharma AG), a contrast agent under development for MRA, is an optimized formulation with respect to T1 weighted MRI of the carboxydextran-coated ferucarbotran (see also Resovist® formerly SHU 555 A, Bayer Schering Pharma AG).
spacer

• View the DATABASE results for 'SHU 555 C' (2).Open this link in a new window

MRI Resources 
Stimulator pool - Journals - Quality Advice - Liver Imaging - Pregnancy - Intraoperative MRI
 
     1 - 5 (of 6)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Your new MRI scanner in 2020 will be shipped from :
China 
Europe 
India 
Japan 
USA 
other 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2014 SoftWays. All rights reserved. [ 1 October 2014]
Terms of Use | Privacy Policy | Advertising
 [last update: 2014-09-28 05:33:09]